These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 26125862)
1. Apelin polymorphism predicts blood pressure response to losartan in older Chinese women with essential hypertension. Jia J; Men C; Tang KT; Zhan YY Genet Mol Res; 2015 Jun; 14(2):6561-8. PubMed ID: 26125862 [TBL] [Abstract][Full Text] [Related]
2. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. Schjoedt KJ; Lajer M; Andersen S; Tarnow L; Rossing P; Parving HH Scand J Clin Lab Invest; 2006; 66(3):173-80. PubMed ID: 16714246 [TBL] [Abstract][Full Text] [Related]
3. Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction. Mayer B; Lieb W; Götz A; König IR; Kauschen LF; Linsel-Nitschke P; Pomarino A; Holmer S; Hengstenberg C; Doering A; Loewel H; Hense HW; Ziegler A; Erdmann J; Schunkert H J Hypertens; 2006 Oct; 24(10):1965-70. PubMed ID: 16957555 [TBL] [Abstract][Full Text] [Related]
4. T1198C polymorphism of the angiotensinogen gene and antihypertensive response to angiotensin-converting enzyme inhibitors. Yu H; Lin S; Liu G; Zhang Y; Deng C; Ma W Hypertens Res; 2005 Dec; 28(12):981-6. PubMed ID: 16671337 [TBL] [Abstract][Full Text] [Related]
5. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. Weiss RJ; Stapff M; Lin Y Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study. Hong BK; Park CG; Kim KS; Yoon MH; Yoon HJ; Yoon JH; Yang JY; Choi YJ; Cho SY Am J Cardiovasc Drugs; 2012 Jun; 12(3):189-95. PubMed ID: 22462558 [TBL] [Abstract][Full Text] [Related]
7. [The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan]. Zhao C; Wang YY; Xiao ZX; Wang YP; Zhang QY Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):428-31. PubMed ID: 17680535 [TBL] [Abstract][Full Text] [Related]
8. Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. Kohlmann O; Roca-Cusachs A; Laurent S; Schmieder RE; Wenzel RR; Fogari R Adv Ther; 2009 Mar; 26(3):313-24. PubMed ID: 19330493 [TBL] [Abstract][Full Text] [Related]
9. Efficacy/safety of olmesartan medoxomil versus losartan potassium in naïve versus previously treated subjects with hypertension. Punzi HA; Lewin A; Li W; Chavanu KJ Adv Ther; 2012 Jun; 29(6):524-37. PubMed ID: 22763801 [TBL] [Abstract][Full Text] [Related]
10. Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment. Jiang X; Sheng HH; Lin G; Li J; Lu XZ; Cheng YL; Huang J; Xiao HS; Zhan YY Chin Med J (Engl); 2007 May; 120(9):782-6. PubMed ID: 17531119 [TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study. Kang SM; Youn JC; Chae SC; Park CG; Yang JY; Kim MH; Hong TJ; Kim CH; Kim JJ; Shin DG; Jeong JW; Yoon JH; Park SH; Kwon J; Cho SY Clin Ther; 2011 Dec; 33(12):1953-63. PubMed ID: 22136978 [TBL] [Abstract][Full Text] [Related]
12. Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients. Göktaş MT; Pepedil F; Karaca Ö; Kalkışım S; Cevik L; Gumus E; Guven GS; Babaoglu MO; Bozkurt A; Yasar U Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2460-7. PubMed ID: 27338075 [TBL] [Abstract][Full Text] [Related]
13. Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study. Neutel JM; Kolloch RE; Plouin PF; Meinicke TW; Schumacher H; J Hum Hypertens; 2003 Aug; 17(8):569-75. PubMed ID: 12874615 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Lacourcière Y; Gil-Extremera B; Mueller O; Byrne M; Williams L Int J Clin Pract; 2003 May; 57(4):273-9. PubMed ID: 12800457 [TBL] [Abstract][Full Text] [Related]
15. [Association between G-protein beta3 subunit (GNB(3)) gene C825T polymorphism, hypertension, insulin resistance and obesity]. Chen YY; Li GW; Li CM; Huang XH; Ju ZY; Sun SX; Cai H; Hui RT Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(14):1229-32. PubMed ID: 12930636 [TBL] [Abstract][Full Text] [Related]
16. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350 [TBL] [Abstract][Full Text] [Related]
17. G-protein beta3-subunit gene variant, blood pressure and erythrocyte sodium/lithium countertransport in essential hypertension. Poch E; González-Núñez D; Compte M; De la Sierra A Br J Biomed Sci; 2002; 59(2):101-4. PubMed ID: 12113397 [TBL] [Abstract][Full Text] [Related]
18. Aldosterone synthase (CYP11B2) C-344T polymorphism affects the association of age-related changes of the serum C-reactive protein. Oki K; Yamane K; Satoh K; Nakanishi S; Yamamoto H; Kohno N Hypertens Res; 2010 Apr; 33(4):326-30. PubMed ID: 20094057 [TBL] [Abstract][Full Text] [Related]
19. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Lacourcière Y; Neutel JM; Schumacher H Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450 [TBL] [Abstract][Full Text] [Related]
20. G protein beta3 subunit gene polymorphism in Turkish hypertensives. Alioğlu E; Ercan E; Tengiz I; Yildiz A; Onsel Türk U; Saygi S; Cam FS; Berdeli A Anadolu Kardiyol Derg; 2008 Oct; 8(5):331-5. PubMed ID: 18849222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]